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Proteolytic enzymes such as matrix metalloproteases (MMPs) and
various serine proteases are known to mediate cancer progression
and metastasis (Mignatti and Rifkin, 1993; Sorsa et al, 1997;
Mazzieri et al, 1997; Blasi and Stoppelli, 1999; Ramos-DeSimone
et al, 1999; McCawley and Matrisian, 2000). The importance of
trypsin, a major serine protease, has been evidenced more recently
in many cancers including tumours in the digestive tract: 
1. Extra-pancreatic production of trypsin was shown in ovarian
(Hirahara et al, 1995), lung (Kawano et al, 1997), gastric
(Miyata et al, 1998) and colonic tumours (Bernard-Perrone 
et al, 1998; Miyata et al, 1999); 
2. The trypsinogen gene is significantly expressed in vascular
endothelial cells around gastric tumours (Koshikawa et al,
1997); 
3. Elevated serum trypsin level has been reported in some diges-
tive cancers (Hedstrom et al, 1996; Ichikawa et al, 2000); 
4. Overexpression of exogenous trypsinogen cDNA in human
gastric cancer cells increases their tumourigenicity in nude
mice (Miyata et al, 1998); 
5. Serine protease inhibitors suppress carcinogenesis in many
different in vivo and in vitro assay systems (Kennedy, 1994;
Kennedy, 1998). 
Although trypsin, like other proteolytic enzymes, contributes to
cancer progression by degradation of extracellular matrix proteins
(Koshikawa et al, 1992), a direct effect on tumour cell proliferation
is conceivable. Indeed, it has long been known that trypsin stimu-
lates cell division of fibroblasts by acting at the cell surface
(Blumberg and Robbins, 1975; Carney and Cunningham, 1977).
This is in line with recent studies suggesting that the action of
trypsin can be mediated not only by its classical ability to catalyze
the hydrolysis of various proteins, but also through specific
cleavage and activation of a cell surface receptor, the protease-acti-
vated receptor-2 (PAR-2) (Nystedt et al, 1994; Bohm et al, 1996b;
Hollenberg, 1996). 
PAR-2 is the second member of a new subfamily of G protein-
coupled receptors activated by proteolytic cleavage (Dery et al,
1998) that also includes PAR-1, PAR-3 and PAR-4 (Vu et al, 1991;
Ishihara et al, 1997; Xu et al, 1998), which are receptors for
thrombin. PAR-2 cleavage by trypsin exposes a new amino
terminus peptide that functions as tethered ligand (Nystedt et al,
1994; Bohm et al, 1996b). This new ligand binds to the core of the
receptor and initiates signal transduction resulting in stimulation
of phosphoinositide breakdown and cytosolic calcium mobiliza-
tion (Nystedt et al, 1994; Dery et al, 1998). A short synthetic
peptide (activating peptide-2 or AP2) corresponding to the new
amino-terminus exposed after trypsin cleavage, is able to activate
selectively the PAR-2 receptor and mimic the cellular effects of
trypsin (Nystedt et al, 1994, 1995; Saifeddine et al, 1996; Bohm 
et al, 1996b). Therefore AP2 or AP2-modified sequences
(Vergnolle, 2000) have become useful specific pharmacological
ligands used to assess the biological function of PAR-2 in several
biological systems. 
The presence of PAR-2 has been revealed in a variety of tissues
(Nystedt et al, 1994; D’Andrea et al, 1998); in particular high
expression has been observed in the gastrointestinal tract (Nystedt
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et al, 1995; Bohm et al, 1996b; Kong et al, 1997; D’Andrea et al,
1998; Nguyen et al, 1999). These receptors are functional since
activation of PAR-2 by trypsin or AP2 induces ion secretion and
prostaglandin production in normal intestine (Kong et al, 1997;
Vergnolle et al, 1998). Despite increasing evidence for a role of
PAR-2 in normal digestive epithelia, the expression and functional
consequences of activation of PAR-2 in digestive cancers has not
yet been reported. 
The experiments described in this article were carried out to
determine the expression of PAR-2 in human colon cancer cells
and to investigate the possible role of trypsin and PAR-2 in colon
cancer cell proliferation. We used Northern blot, reverse-transcrip-
tion polymerase chain reaction (RT-PCR) and immunofluores-
cence to characterize PAR-2 in a large collection of human colon
cancer cell lines. We further demonstrated its functional coupling
to the mobilization of intracellular calcium. Finally, we provided
evidence for a major role of PAR-2 in the proliferation of colon
cancer cells by showing that its natural activator, trypsin, or the
synthetic PAR-2-activating peptide SLIGKV promoted a dramatic
increase of colon cancer cell number in culture. The effect of
trypsin can account for as much as 30% of the effect of fetal calf
serum, which reached a maximum of ~10-fold above serum-
starved controls. These data provide the first evidence that PAR-2
is prevalent in human colon cancer and that it plays a very signifi-
cant role in the control of colon cancer cell growth. 
MATERIALS AND METHODS 
Reagents 
The activating peptide AP2 (SLIGKV), the reverse sequence RP
(VKGILS) and the peptide (SLIGKVDGTSHVTG) were obtained
from Neosystem (Strasbourg, France). Trypsin (16 000 u.mg–1)
and goat anti-mouse IgG coupled to fluorescein were from Sigma
chemical Co. (St Louis, MO, USA). Fura-2/AM and pleuronic
acid were obtained from Molecular probes (Leiden, Netherlands).
Synthetic oligonucleotides, fetal calf serum (FCS), DMEM, RPMI
1640 and HAM F12 were from GIBCO-BRL (Cergy-Pontoise,
France). Hybond membrane and radioactive isotope [32P] were
from Amersham (Les Ullis, France). Human PAR-2 cDNA
(Nystedt et al, 1995) was generously provided by Dr Sundelin
(Lund University, Lund, Sweden). Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) cDNA was obtained from Clontech
(Montigny, France). All other chemicals of the highest purity
commercially available were from Bioprobe (Paris, France) or
Interchim (Asnière, France). 
Cell lines 
The human colon cancer cell lines HT-29, SW480, HCT116,
Caco-2, HCT-8, LoVo, LS-174T, SW620 and T84 were obtained
from ATCC (Rockville, MD, USA). The Cl.19A cell line was
isolated from the parental HT-29 cell line and exhibits enterocyte-
like differentiation (Augeron and Laboisse, 1984). The main char-
acteristics of the cell lines used in this study are described
elsewhere (Zweibaum et al, 1991). HT-29 (passage 164–170),
SW480 (passage 52–63), SW620 (passage 8–12), HCT116
(passage 14–20), Caco-2 (passage 20–23), HCT-8 (passage
20–30), LoVo (passage 4–48), LS-174T (passage 47–55), T84
(passage 63–80) and Cl.19A (passage 13–15) were routinely
cultured in 25 cm2 plastic flasks (Costar, Cambridge, MA, USA)
as recommended by ATCC. They were maintained at 37˚C in a
humidified atmosphere of 5% CO2/air in DMEM containing
4.5 g/l glucose, supplemented with 10% fetal calf serum (FCS)
with the exception of Caco-2 cells, which were maintained in 20%
FCS and 1% non-essential amino acids. 
Proliferation assay 
Determination of cellular proliferation was accomplished by direct
cell count. Colon cancer cells were seeded sparsely (5000
cells/well) in 96 cluster wells (Costar) and allowed to attach for 3 d.
The culture medium containing 10% FCS was DMEM for HT-29,
SW480, HCT116, Caco-2, LS-174T and SW620 cell lines, HAM
F12 for LoVo and T84 cell lines and RPMI 1640 for the HCT-8 cell
line (Zweibaum et al, 1991). The medium was removed and
attached cells were rinsed twice with serum-free medium. They
were then grown in 200 µ l of culture medium without FCS for 
48 h. The cells in representative wells were counted and then
200 µ l of a fresh serum-free medium were added with or without
trypsin, SLIGKV or VKGILS at different concentrations. A quan-
tity of 10% of FCS was used as a positive control. After different
times in culture, cells were detached from triplicate wells by trypsin
(0.25% wt/v)–EDTA (0.02% wt/v) and counted in a haemacy-
tometer. Cell death was evaluated with trypan blue. No significant
cell death was observed after treatment with AP2, regardless of the
concentration, or with trypsin up to 1 nM concentration. 
RNA blot analysis 
Total cellular RNA was extracted by acid guanidinium thiocyanate
technique (Chirgwin et al, 1979). Samples (10 µ g) of total RNA
were electrophoresed in 1.5% agarose gels containing 0.6%
formaldehyde, blotted onto hybond N Plus membranes and
hybridized to a full-length 32P-labelled PAR-2 cDNA probe
overnight at 42˚C in 1 M NaCl, 50% (v/v) formamide, 10%
dextran sulfate and 1% SDS. Blots were washed for 20 min with
2X SSC (1X SSC = 150 mM NaCl and 15 mM sodium citrate, 
pH 7.0), 0.1% SDS at room temperature and then for 30 min 
with 0.2X SSC, 0.1% SDS at 65˚C. Autoradiograms were exposed
at – 70˚C. 
Reverse-transcription polymerase chain reaction
(RT-PCR) 
A quantity of 4 µ g of total RNA were reverse transcribed using
oligo (dT) primer. Amplifications were conducted using the same
resulting cDNAs. Of the cDNA mixture, 25% was amplified using
human PAR-2 sense primer 5′ TCC TGC AGT GGC ACC ATC
CA3′ and antisense primer 5′ TTG CCT TCT TCC TGG AGT
GC3′ . GAPDH cDNA amplification was used as an internal
control with sense primer 5’TCG GAG TCA ACG GAT TTG GTC
GTA 3′ and antisense primer 5′ AGC CTT CTC CAT GGT GGT
GAA GA 3′ . Each of the 30 cycles of amplification was performed
as follows: 94˚C for 40 s, 50˚C for 40 s and 72˚C for 
40 s. PCR products were identified by electrophoresis in 2%
agarose gel followed by ethidium bromide staining and blotting by
hybridization with 32P-labelled PAR-2 full length cDNA or 32P-
labelled GADPH cDNA in 5X SSPE, 5X Denhardt’s and 0.5%
SDS at 65˚C. Blots were washed for 20 min with 2X SSC, 0.1%
SDS at room temperature and then twice for 30 min with 0.1X
SSC, 0.1% SDS at 65˚C. Autoradiograms were exposed at –70˚C. 
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Indirect immunofluorescence was performed on colon cancer cells
grown on glass coverslips. The antibodies (SAM11) used in our
study were raised against the synthetic peptide SLIGKVDGT-
SHVTG, corresponding to residues 37–50 of the human PAR-2
sequence and have been previously characterized (Molino et al,
1997b; 1998). Cells were washed 3 times in PBS and were then
incubated with PBS containing 2% BSA for 15 min prior to appli-
cation of the primary anti-PAR-2 antibody for 2 h at room temper-
ature at a 1:200 dilution. Cells were washed twice for 5 min in
PBS containing 1% BSA and secondary antibody, goat anti-mouse
IgG coupled to fluorescein, was applied for 45 min at room
temperature. The cells were washed again in PBS containing 1%
BSA, fixed in 2% paraformaldehyde and finally washed in PBS.
The cells were then mounted in glycergel medium (DAKO, High
Wycombe, UK). Images were examined on a Leica (Reuil-
Malmaison, France) inverted DM IRB microscope using the N2.1
filter (515–560 nm band pass filter). 
Intracellular calcium measurement 
Intracellular calcium concentrations of monolayers of colon
cancer cells were measured using the fluorescence indicator Fura-
2/AM. The cells (1 × 103/well) were seeded onto the centre of
glass coverslips in cloning cylinders (0.2 cm2 × 0.8 cm) and
cultured for 3 d. The cells attached to coverslips were then loaded
with 5 µ M Fura-2/AM in Hepes-buffered saline (135 mM NaCl,
4.6 mM KCl, 1.2 mM MgCl2, 11 mM Hepes, 11 mM glucose, and
1.5 mM CaCl2 at pH 7.4) containing 0.01% pleuronic acid in the
dark for 60 min at 37˚C. Then, the cells were washed 3 times with
the same buffer and coverslips were placed at the bottom of an
open perfusion chamber built for microscope work. The chamber
was placed on the stage of an inverted fluorescence microscope
(Diaphot, NIKON) and maintained at 37˚C in a climate box. A
flow rate of 
1 ml/min was used during the whole experiment. The time necessary
for a complete change of the medium in the chamber was 140 s.
This delay was taken into account in the graphical representations.
The microscope was equipped with a × 40 fluor oil-immersion
objective. A selected area of cells was excited at 340 nm and 380
nm alternately (every 2 s) and the fluorescence intensity emitted at
510 nm was measured with a PhotoscanII micro-fluorimeter
(Photon Technology International, Kontron, France). The
measurements of successive 340 nm/380 nm fluorescence ratios
reflect the cytosolic concentration of Ca2+. 
Statistical analysis 
Experiments were performed in triplicate and results are expressed
as mean ± SEM. Statistical significance of differences between
mean values was assessed with the Student’s t-test for unpaired
data. A P value of < 0.05 was regarded as statistically significant. 
RESULTS 
Expression of PAR-2 receptor by human colon cancer
cell lines 
Since no radioactive ligand exists yet for detecting PAR-2, we first
investigated the presence of specific PAR-2 mRNA transcripts in
total RNA extracted from postconfluent human colon cancer cell
lines in culture. Using 10 cell lines exhibiting different pheno-
types, a single 3.5 kb transcript was detected in Caco-2, HT-29,
T84, Cl.19A, SW480 and HCT-8 cells (Figure 1). In contrast,
PAR-2 mRNA was barely detectable by Northern blot analysis in
other colon cancer cell lines including LS-174T, LoVo, SW620
and HCT116 (Figure 1). These data suggest that significant PAR-2
mRNA expression is detected in about 60% of colon cancer cell
lines with this technique. RT-PCR experiments using conditions
for maximal amplifications (see Materials and methods) revealed a
single PCR product of the expected size (505 bp) in LS-174T,
LoVo, SW620 and HCT116 cell lines (Figure 2), suggesting that
they do express a very low level of mRNA. 
Two observations indicated that the expression of PAR-2
mRNA is not correlated to the state of differentiation of colon
cancer cells. First, PAR-2 mRNA was similarly detected by
Northern blot in the undifferentiated parent HT-29 cells and in the
polarized Cl.19A cells (Figure 1). Second, PAR-2 mRNA was
expressed by both undifferentiated Caco-2 cells in exponential
growth phase (not shown) and by postconfluent Caco-2 cells
(Figure 1), which exhibit enterocyte-like differentiation (Laburthe
et al, 1987; Zweibaum et al, 1991; Darmoul et al, 1992). 
In order to provide further evidence for PAR-2 expression, indi-
rect immunofluorescence studies were carried out on some human
774 D Darmoul et al 
British Journal of Cancer (2001) 85(5), 772–779 © 2001 Cancer Research Campaign
C
a
c
o
-
2
H
T
-
2
9
S
W
4
8
0
T
8
4
C
l
.
1
9
A
L
S
-
1
7
4
T
H
C
T
-
8
L
o
V
o
H
C
T
1
1
6
S
W
6
2
0
PAR-2
GADPH
Figure 1 Northern blot analysis of PAR-2 mRNA expression in various human colon cancer cell lines. Total RNA (10 µ g/lane) was electrophoresed in
formaldehyde-containing 1% agarose gel. Blots were first hybridized to human [32P]-labelled PAR-2 cDNA probe. Blots were subsequently hybridized with [32P]-
labelled human GAPDH cDNA probe
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colon cancer cell lines using the SAM11 monoclonal antibody to
human PAR-2. Since this antibody recognizes an extracellular
epitope located in the N-terminal domain of the receptor (Molino
et al, 1998), studies were carried out on non-permeabilized cells.
First, we investigated two cell lines exhibiting expression of PAR-
2 mRNA in Northern blotting experiments, i.e. HT-29 and HCT-8.
These studies allowed us to observe immunolocalization of PAR-2
on the cell surface of HT-29 and HCT-8 cells (Figure 3). No
immunofluorescence was seen when only the second antibody was
applied or when the primary antibody was pre-incubated with its
immunizing peptide (not shown). Since PAR-2 has been shown to
be internalized upon activation by trypsin or activating peptide
AP2 (Bohm et al, 1996a), we also performed immunofluorescence
studies following incubation of HT-29 cells with either activator. It
appeared that cell surface labelling dramatically decreased (Figure
3), further assessing for the relevance of the immunofluorescence.
Since some human colon cell lines appeared to express a low level
of PAR-2 mRNA that could not be detected by Northern blotting
(see above), an immunofluorescence experiment was also carried
out on one such cell line, i.e. LS-174T. No fluorescence could be
detected with LS-174T cells (Figure 3) suggesting a very low
expression, if any, of the PAR-2 protein. 
PAR-2 activators and calcium mobilization 
In order to characterize functional PAR-2 in human colon cancer
cell lines, we first studied the role of PAR-2 activators on intra-
cellular calcium mobilization in HT-29 cells expressing PAR-2
mRNA and PAR-2 protein at cell surface. Trypsin and the PAR-2
activating peptide AP2, corresponding to the neo-ligand formed
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Figure 2 PCR-based detection of PAR-2 mRNA in colon cancer cell lines.
Total RNA extracted from various human colon cancer cells was reverse
transcribed and PCR amplified with either PAR-2 or GAPDH primers. A single
PCR-amplified product of the exact predicted size was visualized for both
primer sets, after electrophoreses in a 2% agarose gel and hybridization with
[32P]-labelled full-length PAR-2 cDNA probe (upper panel) or [32P]-labelled full-
length GAPDH cDNA proble (lower panel)
A B
C D
Figure 3 Detection of PAR-2 in human colon cancer cells by immunofluorescence. Cells were fixed using 2% paraformaldehyde and immunostained with
SAM11 monoclonal antibody as outlined in Materials and methods. (A) PAR-2 protein is seen on the cell surface of confluent HT-29 cells (400 × ). (B) HT-29
cells incubated at 37˚C for 15 min with AP2 (100 µ M) show very little immunofluorescence with SAM11 (400 × ). (C) Cell surface staining is evident in HCT-8
cells (400 × ). (D) No immunofluorescence was observed on LS-174T cell line (400 × ) stained with SAM11
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after receptor cleavage (SLIGKV), were used. As shown in 
Figure 4, activation of PAR-2 in HT-29 cells by 10 nM trypsin
resulted in a rapid rise of intracellular calcium transients. After a
first challenge by 10 nM trypsin followed by a 10-minute washing,
a further challenge by 10 nM trypsin produced no calcium
response (not shown). Although in our assay conditions it was
difficult to determine dose-response curves, it is worth mentioning
that 100 nM trypsin gave a response similar to that of 10 nM
trypsin, while 1 nM enzyme only produced a small rise of intracel-
lular calcium (not shown). The peptide AP2 also elicited a rapid
rise of intracellular calcium (Figure 4). The peptide was active at
100 µ M (Figure 4) or 50 µ M, while 10 µ M AP2 gave a small
response (not shown). As a control it was verified that 100 µ M
reverse peptide (RP), whose sequence is VKGILS, had no effect
on calcium mobilization in HT-29 cells (Figure 4). We also carried
out experiments in which HT-29 cells were assayed in Ca2+-free
medium upon exposure to AP2 (100 µ M) or trypsin (10 nM). The
calcium responses to AP2 (Figure 4) or trypsin (not shown) were
unaffected, indicating that Ca2+ derives from intracellular pools. 
The functional property of PAR-2 with respect to calcium mobi-
lization was also studied in other human colon cancer cell lines
exhibiting (Cl.19A, HCT-8) or not (LS-174T) detectable mRNA
levels in Northern blot experiments (Figure 1). The peptide AP2
(100 µ M) elicited a rapid rise of intracellular calcium transients in
Cl.19A and HCT-8 cells (Figure 4). In contrast, no response could
be observed in LS-174T cells (not shown). Neither was there any
calcium mobilization in LS-174T cells upon challenge with 10 nM
or 100 nM trypsin (not shown). 
PAR-2 activators and cell proliferation 
The potential role of PAR-2 activators on proliferation of human
colon cancer cells was first investigated on HT-29 cells. In the
proliferation assay conditions used (see Materials and methods),
0.1 nM trypsin elicited a highly significant effect on cell prolifera-
tion (Figure 5). A maximal 300% increase of cell number above
basal level was observed upon challenge of cells with 1 nM
trypsin. After incubation with 0.1–1 nM trypsin, cells showed
similar morphology as compared to untreated cells (data not
shown). At a higher enzyme concentration (10 nM), an important
detachment of HT-29 cells from plastic wells occurred and the
proliferation assay was no longer reliable. The peptide AP2 also
elicited a dose-dependent mitogenic response on HT-29 cells
(Figure 5). Maximal response was observed at 100–300 µ M
peptide and represented a 270% increase of cell number, i.e. the
same maximal response as for trypsin (300%). Half-maximal
response was obtained for 47 ± 6 µ M (n = 8) AP2. Unlike trypsin,
AP2 did not induce HT-29 cell detachment regardless of the used
peptide concentration (not shown). Maximal responses elicited by
trypsin or AP2 were very important since they represented 30% of
the maximal mitogenic response induced by 10% FCS, which
reached a maximum of ~10-fold above serum-starved controls (not
shown). The RP had no effect on HT-29 cell proliferation when
tested up to 300 µ M (Figure 5). 
Further studies were carried out in order to investigate the role
of PAR-2 activators trypsin and AP2 on proliferation of other
human colon cancer cell lines. As shown in Figure 6, trypsin
elicited a significant increase of cell number for Cl.19A and HCT-
8 cells though the mitogenic effect is less pronounced than for HT-
29 cells. Trypsin (1 nM)-induced increases of cell number above
basal level represented 231% and 162%, respectively. In sharp
contrast, trypsin had no effect on proliferation of LS-174T cells,
which do not express PAR-2 at cell surface (see earlier). Neither
was there any effect of trypsin on proliferation of HCT116 cells
(Figure 6) that have a low PAR-2 mRNA level (Figure 1). The
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Figure 4 Effect of trypsin and AP2 (SLIGKV) on calcium signalling. HT-29
cells were loaded for 60 min at 37˚C using Fura-2/AM and assayed in
medium containing Ca2+ (A, B) or in Ca2+-free medium (C). The addition of
the activating peptide AP2 (100 µ M), the inactive reverse peptide RP (100
µ M) or trypsin (10 nM) is indicated by arrows. (D) and (E) show Cl.19A and
HCT-8 cells challenged with 100 µ M AP2, respectively. Representative
experiments are shown. Each experiment has been carried out at least
3 times
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Figure 5 Concentration-dependent stimulation of HT-29 cell proliferation by
trypsin or AP2. Cells were seeded in medium containing 10% FCS. After 3 d,
cells were washed and covered with serum-free medium for 48 h. Quiescent
HT-29 cells were grown in serum free-medium with the indicated
concentration of trypsin, synthetic PAR-2 agonist (AP2) or RP. After 96 h cells
from triplicate wells were counted for each condition. Data are mean ± SEM
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peptide AP2 gave responses that are similar to those triggered by
trypsin. Indeed, AP2 stimulated proliferation of Cl.19A and HCT-
8 cells but had no effect on proliferation of LS-174T and HCT116
cells (Figure 6). 
DISCUSSION 
We have found that trypsin strongly stimulates proliferation of
human colon cancer cells in culture. The mitogenic effect is
promoted by low nanomolar concentration of trypsin and is medi-
ated by a G protein-coupled seven-transmembrane domain
receptor, PAR-2. Since PAR-2 expression and mitogenic effect of
trypsin are observed in many colon cancer cell lines, we speculate
that trypsin, and possibly other serine proteases acting at PAR-2,
could represent new important signalling proteins in the control of
colon cancer growth. 
Northern blot analysis showed that PAR-2 mRNA is detectable
in 60% of human colon cancer cell lines examined, e.g. HT-29,
Caco-2, T84, Cl.19A, SW480 and HCT-8. Moreover, RT-PCR
analysis provided evidence for the presence of PAR-2 transcripts in
the remaining cell lines, suggesting that they express low levels of
PAR-2 mRNA. A previous report also described PAR-2 transcripts
in some colon cancer cell lines (Bohm et al, 1996b) but did not
assess PAR-2 protein expression and function. In this study,
immunofluorescence experiments showed that PAR-2 protein is
expressed in cell lines exhibiting abundant transcripts such as HT-
29 or HCT-8, whereas no staining could be observed with the anti-
PAR-2 antibodies in cell lines with low expression of transcripts.
The correlation extends to PAR-2 function since trypsin or the
synthetic agonist AP2 promoted calcium mobilization and cell
proliferation in cell lines expressing abundant PAR-2 mRNA and
proteins such as HT-29 or HCT-8 but not in cell lines with a low
number of transcripts or no staining in immunofluorescence studies
such as LS-174T or HCT116. Altogether, our data support the idea
that abundant mRNAs trigger the synthesis of functional PAR-2
protein in many, but not all, colon cancer cell lines. The expression
of abundant PAR-2 mRNA or PAR-2 protein in colon cancer cells
is not correlated with the differentiation phenotype of cells in
culture. Indeed, PAR-2 is detected in cells that undergo enterocyte
like-differentiation such as Caco-2 (Laburthe et al, 1987; Darmoul
et al, 1992) or Cl.19A cells (Augeron and Laboisse, 1984) and also
in cells that do not exhibit enterocyte differentiation markers
(Zweibaum et al, 1991; Darmoul et al, 1992). 
Proliferation of human colon cancer cells is stimulated by
trypsin at very low concentrations in the 0.1–1 nM range (see
Figure 5). These concentrations are much lower than the concen-
trations of trypsin required for hydrolysis of proteins in the
duodenal lumen (Green and Nasset, 1980). Further, they are lower
than the concentrations of trypsin required to trigger PAR-2-
mediated regulation of short-term events such as prostaglandin
secretion in small intestine enterocytes (Kong et al, 1997) or net
electrogenic ion transport in pancreatic duct epithelial cells
(Nguyen et al, 1999) that are in the micromolar range. This
suggests that colonic cancer cells may have an exquisite sensitivity
to trypsin. However, the effects of trypsin on colonic cancer cell
proliferation are clearly mediated by PAR-2 since we showed that
the specific agonist of PAR-2, AP2 (Blackhart et al, 1996;
Hollenberg et al, 1997) also promoted cell proliferation, mimic-
king the trypsin effect. In contrast the reverse peptide with the
reverse AP2 peptide sequence was devoid of any mitogenic effect.
The same held true for control of calcium mobilization in colon
cancer cells with AP2 mimicking trypsin effect and the reverse
peptide being inactive (see Figure 4). As previously reported by
others (see Vergnolle, 2000 for a review) AP2 is a low potency
agonist compared to trypsin. The differences in the potency of
AP2 are probably due to the non-sufficient presentation of AP2 to
the binding domain of PAR-2. The same anchored amino acid
sequence may be presented in a better conformation to the binding
domain during the physiological activation of PAR-2 by trypsin. 
Altogether, our data are consistent with a PAR-2-mediated
control of colon cancer cell proliferation by trypsin. Trypsin or
AP2 were very efficient in promoting colon cancer cell prolifera-
tion since, at maximally active concentrations, their effect repre-
sented up to a 300% increase of cell number in HT-29 cells. The
effect of trypsin even represented 30% of the maximal mitogenic
response induced by 10% FCS in HT-29 cells. Considering the
high efficacy and potency of trypsin in promoting colon cancer cell
proliferation, this serine protease and possibly other serine
proteases acting at PAR-2 (see later), should be considered as
growth factors that could be as significant as classical growth
factors (Singh and Rubin, 1993; Normanno et al, 1998) or peptide
hormones (Maoret et al, 1999; Singh et al, 2000) for colon cancer.
Although the intracellular pathways responsible for PAR-2-
mediated stimulation of colon cancer cell proliferation by trypsin
are beyond the scope of this paper, it is worth noting that activation
of PAR-2 results in PKC-dependent activation of MAP kinase
cascade (Belham et al, 1996; DeFea et al, 2000) and phosphoryla-
tion of Src homology-2 domain-containing protein-tyrosine phos-
phatase SHP2 (Yu et al, 1997). These events are consistent with
the PAR-2-mediated mitogenic responses that were observed in
our studies. 
The efficient and potent mitogenic action of trypsin on colon
cancer cells raises the question of the endogenous source(s) of
trypsin or other serine proteases that could activate PAR-2 in situ
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Figure 6 Ability of PAR-2 ligands (AP2, trypsin) to induce mitogenesis in
different human colon cancer cell lines. Cells were seeded in medium
containing 10% FCS. After 3 d, cells were washed and covered with serum-
free medium for 48 h. Quiescent human colon cancer cells were then grown
for 96 h in serum free-medium without (control) or with 100 µ M AP2 (AP2), or
with 1 nM trypsin (Trypsin). Cells from triplicate wells were counted for each
condition. Data are mean ± SEM. *P < 0.001, Trypsin- or AP2-treated cells vs
control cells (Student’s t-test)
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in colon cancer. Although low trypsin activity originating from
exocrine pancreas may remain in the luminal content of the colon
(Bustos et al, 1994), it is by far lower than the luminal trypsin
content of the upper small intestine. In this context, it is worth
pointing out that several lines of evidence indicate the importance
of locally secreted trypsin at the vicinity of colon tumours: (1)
trypsin was shown to be expressed by the large intestine
(Koshikawa et al, 1998). Normal epithelial cells surrounding colon
tumour cells are a likely source of active trypsin; (2) human colon
cancer cells themselves were shown to express trypsin and
trypsinogen (Bernard-Perrone et al, 1998; Miyata et al, 1999); (3)
recent studies on gastric cancer indicate that blood vessels
surrounding tumours express trypsin, whereas other blood vessels
do not (Koshikawa et al, 1997). Trypsin is also present in serum at
nanomolar concentrations and could diffuse from blood to tumour
cells. Moreover, elevated trypsin levels were reported in the serum
of patients with gastric carcinoma (Ichikawa et al, 2000),
suggesting that serum may be an important source of trypsin in
cancerous patients. Finally, many studies showed that tryptase
originating from mast cells, also activates PAR-2 (Mirza et al,
1997; Molino et al, 1997a; Akers et al, 2000) though with a
reduced potency and efficacy as compared to trypsin (Molino et al,
1997a). Since mast cells are abundant in colonic mucosa
(Aldenborg and Enerback, 1994) and have been found to infiltrate
colon tumour, it can be suggested that tryptase is a putative acti-
vator of PAR-2 in colonic tumours. In our recent studies, we
showed that tryptase was also able to promote colonic cancer cell
proliferation (Darmoul et al, unpublished results). Since the initial
characterization of PAR-2 and its activation by trypsin, other acti-
vating serine proteases have been reported. These include tryptase,
the membrane-type serine proteasel, the tissue factor VIIa Xa
complex (see O’Brien et al, 2001 for a review), a proteinase
isolated from Porphyromonas gingivalis (Vergnolle, 2000) and
acrosin (Smith et al, 2000). Among all these serine proteases, only
tryptase and the tissue factor VIIa Xa complex might reasonably
be expected to be present within the colonic cancer environment.
Whether these proteases act on colonic cancer cell proliferation
remains to be demonstrated. 
In conclusion, we have shown the expression of functional PAR-
2 in human colon cancer cells and demonstrated that trypsin has a
potent and efficient mitogenic effect on colon cancer cells. These
data support the hypothesis that trypsin can play an important role
as a signalling protein in the growth of tumour of the colon. 
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